CN104284896B - 取代的咪唑并哒嗪 - Google Patents

取代的咪唑并哒嗪 Download PDF

Info

Publication number
CN104284896B
CN104284896B CN201380024787.9A CN201380024787A CN104284896B CN 104284896 B CN104284896 B CN 104284896B CN 201380024787 A CN201380024787 A CN 201380024787A CN 104284896 B CN104284896 B CN 104284896B
Authority
CN
China
Prior art keywords
cyclopropyl
imidazo
amino
methylbenzamide
trifluoropropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380024787.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN104284896A (zh
Inventor
M·科皮茨
U·克拉尔
A·M·温内尔
R·诺伊豪斯
G·西迈斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Bayer Intellectual Property GmbH
Original Assignee
Bayer Pharma AG
Bayer Intellectual Property GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Bayer Intellectual Property GmbH filed Critical Bayer Pharma AG
Publication of CN104284896A publication Critical patent/CN104284896A/zh
Application granted granted Critical
Publication of CN104284896B publication Critical patent/CN104284896B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201380024787.9A 2012-03-14 2013-03-11 取代的咪唑并哒嗪 Expired - Fee Related CN104284896B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12159455.0 2012-03-14
EP12159455 2012-03-14
EP13154139 2013-02-06
EP13154139.3 2013-02-06
PCT/EP2013/054841 WO2013135612A1 (en) 2012-03-14 2013-03-11 Substituted imidazopyridazines

Publications (2)

Publication Number Publication Date
CN104284896A CN104284896A (zh) 2015-01-14
CN104284896B true CN104284896B (zh) 2016-06-01

Family

ID=47913379

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380024787.9A Expired - Fee Related CN104284896B (zh) 2012-03-14 2013-03-11 取代的咪唑并哒嗪

Country Status (9)

Country Link
US (1) US9512126B2 (enExample)
EP (1) EP2825540B1 (enExample)
JP (1) JP6166289B2 (enExample)
CN (1) CN104284896B (enExample)
AR (1) AR090323A1 (enExample)
CA (1) CA2867061A1 (enExample)
ES (1) ES2605946T3 (enExample)
UY (1) UY34677A (enExample)
WO (1) WO2013135612A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6166289B2 (ja) 2012-03-14 2017-07-19 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾピリダジン
CA2914745A1 (en) 2013-06-11 2014-12-18 Bayer Pharma Aktiengesellschaft Prodrug derivatives of substituted triazolopyridines
AP2015008915A0 (en) * 2013-06-13 2015-12-31 Bayer Pharma AG Combination of a imidazopyridazine derivative and a mitotic agent for the treatment of cancer
EP3283642B1 (en) 2015-04-17 2023-10-11 Netherlands Translational Research Center Holding B.V. Prognostic biomarkers for ttk inhibitor chemotherapy
CN107847580B (zh) 2015-07-07 2022-08-12 扬森疫苗与预防公司 针对rsv的疫苗
GB201907616D0 (en) * 2019-05-29 2019-07-10 Galapagos Nv Novel compounds and pharmaceutical compositons thereof for the treatment of diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120059162A1 (en) * 2009-07-30 2012-03-08 Oncotherapy Science, Inc. Fused imidazole derivative having ttk inhibitory action
WO2012032031A1 (en) * 2010-09-10 2012-03-15 Bayer Pharma Aktiengesellschaft Substituted imidazopyridazines

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
PL332040A1 (en) 1996-08-28 1999-08-16 Pfizer Substitution 6,5-heterobicyclic derivatives
ES2235331T3 (es) 1997-05-28 2005-07-01 Aventis Pharmaceuticals Inc Compuestos quinolina y quinoxalina que inhiben el factor de crecimiento derivado de plaquetas y/o tirosina quinasas p561ck.
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
JP2004346016A (ja) 2003-05-22 2004-12-09 Otsuka Chemical Co Ltd トリフルオロメチルキノキサリン化合物、その製造方法、及び有害生物防除剤
JP4499721B2 (ja) 2003-06-30 2010-07-07 ヒフ バイオ，インク． 化合物、組成物および方法
EP1799680A2 (en) 2004-10-07 2007-06-27 Warner-Lambert Company LLC Triazolopyridine derivatives as antibacterial agents
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
HRP20100378T1 (hr) 2006-05-31 2010-08-31 Galapagos N.V. Spojevi triazolopirazina učinkoviti za tretman degenerativnih i upalnih bolesti
CA2658725A1 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
JP5336375B2 (ja) 2006-08-30 2013-11-06 セルゾーム リミテッド キナーゼ阻害剤としてのトリアゾール誘導体
WO2008133192A1 (ja) * 2007-04-19 2008-11-06 Takeda Pharmaceutical Company Limited 縮合イミダゾール化合物およびその用途
TW200902008A (en) 2007-05-10 2009-01-16 Smithkline Beecham Corp Quinoxaline derivatives as PI3 kinase inhibitors
CN101801966A (zh) 2007-07-18 2010-08-11 诺瓦提斯公司 双环杂芳基化合物和它们作为激酶抑制剂的用途
JP2010535804A (ja) 2007-08-09 2010-11-25 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害薬としてのキノキサリン誘導体
EP2212326A1 (en) 2007-08-23 2010-08-04 AstraZeneca AB 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders
CA2691448A1 (en) 2007-08-31 2009-03-05 Dominique Swinnen Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
UA102828C2 (en) 2007-11-27 2013-08-27 Целльзом Лимитед Amino triazoles as p13k inhibitors
JP5599783B2 (ja) 2008-05-30 2014-10-01 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
WO2010092015A1 (en) 2009-02-10 2010-08-19 Cellzome Limited Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors
EP2396324A1 (en) 2009-02-13 2011-12-21 Fovea Pharmaceuticals Ý1, 2, 4¨triazolo ý1, 5 -a¨pyridines as kinase inhibitors
JP6168773B2 (ja) 2009-04-29 2017-07-26 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾキノキサリン
WO2011026579A1 (en) 2009-09-04 2011-03-10 Bayer Schering Pharma Aktiengesellschaft Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343295A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
PH12012501381A1 (en) 2010-01-15 2012-10-22 Janssen Pharmaceuticals Inc Novel substituted bicyclic triazole derivatives as gamma secretase modulators
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
CN103038235B (zh) 2010-06-01 2015-07-29 拜耳知识产权有限责任公司 取代的咪唑并吡嗪
WO2012080228A1 (en) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft 6-thio-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
US9284317B2 (en) 2010-12-17 2016-03-15 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-a]pyrazines as MPS-1 inhibitors
US20140120087A1 (en) 2011-04-21 2014-05-01 Bayer Intellectual Property Gmbh Triazolopyridines
DK2734205T3 (en) * 2011-07-21 2018-06-14 Tolero Pharmaceuticals Inc Heterocyclic Protein Kinase Inhibitors
JP6166289B2 (ja) 2012-03-14 2017-07-19 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾピリダジン

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120059162A1 (en) * 2009-07-30 2012-03-08 Oncotherapy Science, Inc. Fused imidazole derivative having ttk inhibitory action
WO2012032031A1 (en) * 2010-09-10 2012-03-15 Bayer Pharma Aktiengesellschaft Substituted imidazopyridazines

Also Published As

Publication number Publication date
HK1206022A1 (zh) 2015-12-31
AR090323A1 (es) 2014-11-05
US20150104526A1 (en) 2015-04-16
CN104284896A (zh) 2015-01-14
WO2013135612A1 (en) 2013-09-19
JP2015513559A (ja) 2015-05-14
EP2825540B1 (en) 2016-09-14
ES2605946T3 (es) 2017-03-17
EP2825540A1 (en) 2015-01-21
JP6166289B2 (ja) 2017-07-19
UY34677A (es) 2013-10-31
US9512126B2 (en) 2016-12-06
CA2867061A1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
CN103443100B (zh) 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的取代的6-咪唑并吡嗪
CN102413831B (zh) 取代的咪唑并喹喔啉
CN103687858B (zh) 作为mknk1激酶抑制剂的氨基取代的咪唑并哒嗪
CN102971321B (zh) 咪唑并吡嗪
JP5944497B2 (ja) ヘテロシクリルアミノイミダゾピリダジン
CN104797585B (zh) 氨基咪唑并哒嗪
JP5824040B2 (ja) 置換イミダゾピラジン
CN103582632B (zh) 取代的苯并咪唑
JP5951750B2 (ja) 置換イミダゾピリジン類およびその中間体
CN103429592A (zh) 作为mps-1和tkk抑制剂用于治疗过度增殖性病症的6-取代的咪唑并吡嗪
CN103370322A (zh) 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的2-取代的咪唑并吡嗪
CN103415518A (zh) 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的咪唑并吡嗪
CN103403006B (zh) 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的6-硫代-取代的咪唑并吡嗪
JP6166289B2 (ja) 置換イミダゾピリダジン
CN103649087B (zh) 取代的咪唑并吡啶及其中间体
HK1206022B (en) Substituted imidazopyridazines
HK1187622B (en) 2-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
HK1183297B (en) Imidazopyrazines
HK1179249B (en) Substituted imidazopyrazines
TW201336849A (zh) 經取代咪唑并嗒□
HK1168791B (en) Substituted imidazoquinoxalines

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1206022

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1206022

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160601

Termination date: 20190311